Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) Stock Competitors & Peer Comparison
See ALIVUS.NS's competitors and their performance on the NSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ALIVUS.NS and its NSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALIVUS.NS | ₹1,101.20 | -0.15% | 135.2B | 41.01 | ₹26.85 | +0.45% |
| SUNPHARMA.NS | ₹1,941.10 | -0.66% | 4.7T | 37.71 | ₹51.48 | +0.82% |
| SUNPHARMA.BO | ₹1,941.00 | -0.67% | 4.7T | 38.06 | ₹51.00 | +0.82% |
| DIVISLAB.NS | ₹7,248.50 | -0.77% | 1.9T | 74.64 | ₹97.11 | +0.41% |
| DIVISLAB.BO | ₹7,246.65 | -0.77% | 1.9T | 71.63 | ₹101.17 | +0.41% |
| TORNTPHARM.NS | ₹4,961.50 | -2.05% | 1.7T | 74.34 | ₹66.74 | +0.77% |
| TORNTPHARM.BO | ₹4,959.80 | -2.09% | 1.7T | 75.26 | ₹65.90 | +0.77% |
| ZYDUSLIFE.NS | ₹1,108.70 | -0.46% | 1.1T | 23.04 | ₹48.13 | +0.09% |
| ZYDUSLIFE.BO | ₹1,108.90 | -0.42% | 1.1T | 23.13 | ₹47.94 | +0.09% |
| LUPIN.BO | ₹2,369.45 | -1.11% | 1.1T | 18.60 | ₹127.40 | +0.76% |
Stock Comparison
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA.NS)
ALIVUS.NS vs SUNPHARMA.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SUNPHARMA.NS has a market cap of 4.7T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SUNPHARMA.NS trades at ₹1,941.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SUNPHARMA.NS's P/E ratio is 37.71. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, ALIVUS.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check SUNPHARMA.NS's competition here
Sun Pharmaceutical Industries Limited (BSE: SUNPHARMA.BO)
ALIVUS.NS vs SUNPHARMA.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SUNPHARMA.BO has a market cap of 4.7T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SUNPHARMA.BO trades at ₹1,941.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SUNPHARMA.BO's P/E ratio is 38.06. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, ALIVUS.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check SUNPHARMA.BO's competition here
Divi's Laboratories Limited (NSE: DIVISLAB.NS)
ALIVUS.NS vs DIVISLAB.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, DIVISLAB.NS has a market cap of 1.9T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while DIVISLAB.NS trades at ₹7,248.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas DIVISLAB.NS's P/E ratio is 74.64. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to DIVISLAB.NS's ROE of +0.16%. Regarding short-term risk, ALIVUS.NS is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check DIVISLAB.NS's competition here
Divi's Laboratories Limited (BSE: DIVISLAB.BO)
ALIVUS.NS vs DIVISLAB.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, DIVISLAB.BO has a market cap of 1.9T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while DIVISLAB.BO trades at ₹7,246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas DIVISLAB.BO's P/E ratio is 71.63. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to DIVISLAB.BO's ROE of +0.16%. Regarding short-term risk, ALIVUS.NS is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check DIVISLAB.BO's competition here
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM.NS)
ALIVUS.NS vs TORNTPHARM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, TORNTPHARM.NS has a market cap of 1.7T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while TORNTPHARM.NS trades at ₹4,961.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas TORNTPHARM.NS's P/E ratio is 74.34. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to TORNTPHARM.NS's ROE of +0.26%. Regarding short-term risk, ALIVUS.NS is more volatile compared to TORNTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check TORNTPHARM.NS's competition here
Torrent Pharmaceuticals Limited (BSE: TORNTPHARM.BO)
ALIVUS.NS vs TORNTPHARM.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, TORNTPHARM.BO has a market cap of 1.7T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while TORNTPHARM.BO trades at ₹4,959.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas TORNTPHARM.BO's P/E ratio is 75.26. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to TORNTPHARM.BO's ROE of +0.26%. Regarding short-term risk, ALIVUS.NS is more volatile compared to TORNTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check TORNTPHARM.BO's competition here
Zydus Lifesciences Limited (NSE: ZYDUSLIFE.NS)
ALIVUS.NS vs ZYDUSLIFE.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ZYDUSLIFE.NS trades at ₹1,108.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ZYDUSLIFE.NS's P/E ratio is 23.04. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ZYDUSLIFE.NS's ROE of +0.19%. Regarding short-term risk, ALIVUS.NS is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check ZYDUSLIFE.NS's competition here
Zydus Lifesciences Limited (BSE: ZYDUSLIFE.BO)
ALIVUS.NS vs ZYDUSLIFE.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ZYDUSLIFE.BO trades at ₹1,108.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ZYDUSLIFE.BO's P/E ratio is 23.13. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ZYDUSLIFE.BO's ROE of +0.19%. Regarding short-term risk, ALIVUS.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check ZYDUSLIFE.BO's competition here
Lupin Limited (BSE: LUPIN.BO)
ALIVUS.NS vs LUPIN.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while LUPIN.BO trades at ₹2,369.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas LUPIN.BO's P/E ratio is 18.60. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, ALIVUS.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check LUPIN.BO's competition here
Lupin Limited (NSE: LUPIN.NS)
ALIVUS.NS vs LUPIN.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while LUPIN.NS trades at ₹2,370.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas LUPIN.NS's P/E ratio is 18.61. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, ALIVUS.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check LUPIN.NS's competition here
Mankind Pharma Limited (NSE: MANKIND.NS)
ALIVUS.NS vs MANKIND.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while MANKIND.NS trades at ₹2,507.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas MANKIND.NS's P/E ratio is 50.75. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to MANKIND.NS's ROE of +0.12%. Regarding short-term risk, ALIVUS.NS is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check MANKIND.NS's competition here
Mankind Pharma Limited (BSE: MANKIND.BO)
ALIVUS.NS vs MANKIND.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while MANKIND.BO trades at ₹2,505.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas MANKIND.BO's P/E ratio is 51.05. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to MANKIND.BO's ROE of +0.12%. Regarding short-term risk, ALIVUS.NS is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check MANKIND.BO's competition here
Dr. Reddy's Laboratories Limited (NSE: DRREDDY.NS)
ALIVUS.NS vs DRREDDY.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, DRREDDY.NS has a market cap of 971.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while DRREDDY.NS trades at ₹1,151.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas DRREDDY.NS's P/E ratio is 22.68. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, ALIVUS.NS is less volatile compared to DRREDDY.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check DRREDDY.NS's competition here
Dr. Reddy's Laboratories Limited (BSE: DRREDDY.BO)
ALIVUS.NS vs DRREDDY.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, DRREDDY.BO has a market cap of 971.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while DRREDDY.BO trades at ₹1,152.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas DRREDDY.BO's P/E ratio is 22.68. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, ALIVUS.NS is less volatile compared to DRREDDY.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check DRREDDY.BO's competition here
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS)
ALIVUS.NS vs AUROPHARMA.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AUROPHARMA.NS has a market cap of 881.5B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AUROPHARMA.NS trades at ₹1,532.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AUROPHARMA.NS's P/E ratio is 25.39. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check AUROPHARMA.NS's competition here
Aurobindo Pharma Limited (BSE: AUROPHARMA.BO)
ALIVUS.NS vs AUROPHARMA.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AUROPHARMA.BO has a market cap of 880.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AUROPHARMA.BO trades at ₹1,531.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AUROPHARMA.BO's P/E ratio is 25.38. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check AUROPHARMA.BO's competition here
Laurus Labs Limited (NSE: LAURUSLABS.NS)
ALIVUS.NS vs LAURUSLABS.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, LAURUSLABS.NS has a market cap of 865B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while LAURUSLABS.NS trades at ₹1,601.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas LAURUSLABS.NS's P/E ratio is 97.28. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to LAURUSLABS.NS's ROE of +0.18%. Regarding short-term risk, ALIVUS.NS is less volatile compared to LAURUSLABS.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check LAURUSLABS.NS's competition here
Laurus Labs Limited (BSE: LAURUSLABS.BO)
ALIVUS.NS vs LAURUSLABS.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, LAURUSLABS.BO has a market cap of 865B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while LAURUSLABS.BO trades at ₹1,602.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas LAURUSLABS.BO's P/E ratio is 96.93. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to LAURUSLABS.BO's ROE of +0.18%. Regarding short-term risk, ALIVUS.NS is less volatile compared to LAURUSLABS.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check LAURUSLABS.BO's competition here
Alkem Laboratories Limited (BSE: ALKEM.BO)
ALIVUS.NS vs ALKEM.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ALKEM.BO has a market cap of 673.7B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ALKEM.BO trades at ₹5,635.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ALKEM.BO's P/E ratio is 29.26. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ALKEM.BO's ROE of +0.17%. Regarding short-term risk, ALIVUS.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check ALKEM.BO's competition here
Alkem Laboratories Limited (NSE: ALKEM.NS)
ALIVUS.NS vs ALKEM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ALKEM.NS has a market cap of 673.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ALKEM.NS trades at ₹5,633.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ALKEM.NS's P/E ratio is 34.68. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ALKEM.NS's ROE of +0.17%. Regarding short-term risk, ALIVUS.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check ALKEM.NS's competition here
Glenmark Pharmaceuticals Limited (BSE: GLENMARK.BO)
ALIVUS.NS vs GLENMARK.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GLENMARK.BO has a market cap of 619B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GLENMARK.BO trades at ₹2,193.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GLENMARK.BO's P/E ratio is 45.47. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, ALIVUS.NS is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check GLENMARK.BO's competition here
Glenmark Pharmaceuticals Limited (NSE: GLENMARK.NS)
ALIVUS.NS vs GLENMARK.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GLENMARK.NS has a market cap of 618.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GLENMARK.NS trades at ₹2,192.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GLENMARK.NS's P/E ratio is 35.93. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GLENMARK.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GLENMARK.NS's competition here
Ipca Laboratories Limited (BSE: IPCALAB.BO)
ALIVUS.NS vs IPCALAB.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, IPCALAB.BO has a market cap of 447.3B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while IPCALAB.BO trades at ₹1,762.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas IPCALAB.BO's P/E ratio is 49.16. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to IPCALAB.BO's ROE of +0.14%. Regarding short-term risk, ALIVUS.NS is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check IPCALAB.BO's competition here
Ipca Laboratories Limited (NSE: IPCALAB.NS)
ALIVUS.NS vs IPCALAB.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, IPCALAB.NS has a market cap of 447.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while IPCALAB.NS trades at ₹1,762.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas IPCALAB.NS's P/E ratio is 38.10. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to IPCALAB.NS's ROE of +0.14%. Regarding short-term risk, ALIVUS.NS is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check IPCALAB.NS's competition here
Ajanta Pharma Limited (NSE: AJANTPHARM.NS)
ALIVUS.NS vs AJANTPHARM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AJANTPHARM.NS has a market cap of 421B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AJANTPHARM.NS trades at ₹3,369.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AJANTPHARM.NS's P/E ratio is 39.90. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AJANTPHARM.NS's ROE of +0.25%. Regarding short-term risk, ALIVUS.NS is less volatile compared to AJANTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check AJANTPHARM.NS's competition here
Ajanta Pharma Limited (BSE: AJANTPHARM.BO)
ALIVUS.NS vs AJANTPHARM.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AJANTPHARM.BO has a market cap of 420.3B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AJANTPHARM.BO trades at ₹3,366.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AJANTPHARM.BO's P/E ratio is 39.87. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AJANTPHARM.BO's ROE of +0.25%. Regarding short-term risk, ALIVUS.NS is less volatile compared to AJANTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check AJANTPHARM.BO's competition here
Suven Pharmaceuticals Limited (NSE: SUVENPHAR.NS)
ALIVUS.NS vs SUVENPHAR.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SUVENPHAR.NS's competition here
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO)
ALIVUS.NS vs SUVENPHAR.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SUVENPHAR.BO's competition here
J. B. Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM.NS)
ALIVUS.NS vs JBCHEPHARM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, ALIVUS.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check JBCHEPHARM.NS's competition here
J. B. Chemicals & Pharmaceuticals Limited (BSE: JBCHEPHARM.BO)
ALIVUS.NS vs JBCHEPHARM.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, JBCHEPHARM.BO has a market cap of 386.8B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas JBCHEPHARM.BO's P/E ratio is 52.61. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, ALIVUS.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check JBCHEPHARM.BO's competition here
Emcure Pharmaceuticals Ltd. (NSE: EMCURE.NS)
ALIVUS.NS vs EMCURE.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, EMCURE.NS has a market cap of 356.8B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while EMCURE.NS trades at ₹1,881.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas EMCURE.NS's P/E ratio is 70.98. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, ALIVUS.NS is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check EMCURE.NS's competition here
Wockhardt Limited (BSE: WOCKPHARMA.BO)
ALIVUS.NS vs WOCKPHARMA.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, WOCKPHARMA.BO has a market cap of 299.7B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while WOCKPHARMA.BO trades at ₹1,842.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas WOCKPHARMA.BO's P/E ratio is 140.50. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to WOCKPHARMA.BO's ROE of +0.04%. Regarding short-term risk, ALIVUS.NS is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check WOCKPHARMA.BO's competition here
Piramal Enterprises Limited (NSE: PEL.NS)
ALIVUS.NS vs PEL.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, ALIVUS.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check PEL.NS's competition here
Piramal Pharma Limited (BSE: PPLPHARMA.BO)
ALIVUS.NS vs PPLPHARMA.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, PPLPHARMA.BO has a market cap of 240.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while PPLPHARMA.BO trades at ₹181.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas PPLPHARMA.BO's P/E ratio is -154.68. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, ALIVUS.NS is more volatile compared to PPLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check PPLPHARMA.BO's competition here
Piramal Pharma Limited (NSE: PPLPHARMA.NS)
ALIVUS.NS vs PPLPHARMA.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, PPLPHARMA.NS has a market cap of 240.5B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while PPLPHARMA.NS trades at ₹181.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas PPLPHARMA.NS's P/E ratio is -154.78. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, ALIVUS.NS is more volatile compared to PPLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check PPLPHARMA.NS's competition here
Neuland Laboratories Limited (BSE: NEULANDLAB.BO)
ALIVUS.NS vs NEULANDLAB.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, NEULANDLAB.BO has a market cap of 238.3B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while NEULANDLAB.BO trades at ₹18,570.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas NEULANDLAB.BO's P/E ratio is 64.24. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, ALIVUS.NS is more volatile compared to NEULANDLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check NEULANDLAB.BO's competition here
Neuland Laboratories Limited (NSE: NEULANDLAB.NS)
ALIVUS.NS vs NEULANDLAB.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, NEULANDLAB.NS has a market cap of 237.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while NEULANDLAB.NS trades at ₹18,546.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas NEULANDLAB.NS's P/E ratio is 61.84. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, ALIVUS.NS is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check NEULANDLAB.NS's competition here
Granules India Limited (NSE: GRANULES.NS)
ALIVUS.NS vs GRANULES.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GRANULES.NS has a market cap of 206.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GRANULES.NS trades at ₹833.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GRANULES.NS's P/E ratio is 33.56. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GRANULES.NS's competition here
Granules India Limited (BSE: GRANULES.BO)
ALIVUS.NS vs GRANULES.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GRANULES.BO has a market cap of 206.5B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GRANULES.BO trades at ₹833.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GRANULES.BO's P/E ratio is 33.55. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GRANULES.BO's competition here
AstraZeneca Pharma India Limited (NSE: ASTRAZEN.NS)
ALIVUS.NS vs ASTRAZEN.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ASTRAZEN.NS has a market cap of 200.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ASTRAZEN.NS trades at ₹8,005.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ASTRAZEN.NS's P/E ratio is 106.73. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, ALIVUS.NS is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check ASTRAZEN.NS's competition here
AstraZeneca Pharma India Limited (BSE: ASTRAZEN.BO)
ALIVUS.NS vs ASTRAZEN.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ASTRAZEN.BO has a market cap of 200.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ASTRAZEN.BO trades at ₹8,000.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ASTRAZEN.BO's P/E ratio is 106.65. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, ALIVUS.NS is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check ASTRAZEN.BO's competition here
Eris Lifesciences Limited (NSE: ERIS.NS)
ALIVUS.NS vs ERIS.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ERIS.NS has a market cap of 194.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ERIS.NS trades at ₹1,400.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ERIS.NS's P/E ratio is 39.62. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ERIS.NS's ROE of +0.18%. Regarding short-term risk, ALIVUS.NS is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check ERIS.NS's competition here
Eris Lifesciences Limited (BSE: ERIS.BO)
ALIVUS.NS vs ERIS.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ERIS.BO has a market cap of 194B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ERIS.BO trades at ₹1,398.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ERIS.BO's P/E ratio is 45.36. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ERIS.BO's ROE of +0.18%. Regarding short-term risk, ALIVUS.NS is less volatile compared to ERIS.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check ERIS.BO's competition here
Caplin Point Laboratories Limited (NSE: CAPLIPOINT.NS)
ALIVUS.NS vs CAPLIPOINT.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, CAPLIPOINT.NS has a market cap of 187.5B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while CAPLIPOINT.NS trades at ₹2,467.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas CAPLIPOINT.NS's P/E ratio is 28.99. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to CAPLIPOINT.NS's ROE of +0.20%. Regarding short-term risk, ALIVUS.NS is more volatile compared to CAPLIPOINT.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check CAPLIPOINT.NS's competition here
Caplin Point Laboratories Ltd. (BSE: CAPLIPOINT.BO)
ALIVUS.NS vs CAPLIPOINT.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, CAPLIPOINT.BO has a market cap of 187.3B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while CAPLIPOINT.BO trades at ₹2,464.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas CAPLIPOINT.BO's P/E ratio is 32.80. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to CAPLIPOINT.BO's ROE of +0.20%. Regarding short-term risk, ALIVUS.NS is more volatile compared to CAPLIPOINT.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check CAPLIPOINT.BO's competition here
Natco Pharma Limited (NSE: NATCOPHARM.NS)
ALIVUS.NS vs NATCOPHARM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, NATCOPHARM.NS has a market cap of 165B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while NATCOPHARM.NS trades at ₹921.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas NATCOPHARM.NS's P/E ratio is 12.45. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, ALIVUS.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check NATCOPHARM.NS's competition here
NATCO Pharma Limited (BSE: NATCOPHARM.BO)
ALIVUS.NS vs NATCOPHARM.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, NATCOPHARM.BO has a market cap of 164.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while NATCOPHARM.BO trades at ₹920.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas NATCOPHARM.BO's P/E ratio is 12.42. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, ALIVUS.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check NATCOPHARM.BO's competition here
Cohance Lifesciences Limited (BSE: COHANCE.BO)
ALIVUS.NS vs COHANCE.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, COHANCE.BO has a market cap of 159.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while COHANCE.BO trades at ₹417.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas COHANCE.BO's P/E ratio is 82.45. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to COHANCE.BO's ROE of +0.05%. Regarding short-term risk, ALIVUS.NS is more volatile compared to COHANCE.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check COHANCE.BO's competition here
Cohance Lifesciences Limited (NSE: COHANCE.NS)
ALIVUS.NS vs COHANCE.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, COHANCE.NS has a market cap of 159.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while COHANCE.NS trades at ₹417.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas COHANCE.NS's P/E ratio is 77.60. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to COHANCE.NS's ROE of +0.05%. Regarding short-term risk, ALIVUS.NS is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check COHANCE.NS's competition here
Alembic Pharmaceuticals Limited (BSE: APLLTD.BO)
ALIVUS.NS vs APLLTD.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, APLLTD.BO has a market cap of 157.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while APLLTD.BO trades at ₹796.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas APLLTD.BO's P/E ratio is 21.24. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, ALIVUS.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check APLLTD.BO's competition here
Alembic Pharmaceuticals Limited (NSE: APLLTD.NS)
ALIVUS.NS vs APLLTD.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, APLLTD.NS has a market cap of 156.8B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while APLLTD.NS trades at ₹797.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas APLLTD.NS's P/E ratio is 21.27. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, ALIVUS.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check APLLTD.NS's competition here
Jubilant Pharmova Limited (NSE: JUBLPHARMA.NS)
ALIVUS.NS vs JUBLPHARMA.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, JUBLPHARMA.NS has a market cap of 152.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while JUBLPHARMA.NS trades at ₹965.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas JUBLPHARMA.NS's P/E ratio is 35.62. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, ALIVUS.NS is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check JUBLPHARMA.NS's competition here
Jubilant Pharmova Limited (BSE: JUBLPHARMA.BO)
ALIVUS.NS vs JUBLPHARMA.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, JUBLPHARMA.BO has a market cap of 152.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while JUBLPHARMA.BO trades at ₹962.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas JUBLPHARMA.BO's P/E ratio is 35.50. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, ALIVUS.NS is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check JUBLPHARMA.BO's competition here
Alivus Life Sciences Limited (BSE: ALIVUS.BO)
ALIVUS.NS vs ALIVUS.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ALIVUS.BO has a market cap of 135.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ALIVUS.BO trades at ₹1,101.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ALIVUS.BO's P/E ratio is 24.51. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ALIVUS.BO's ROE of +0.05%. Regarding short-term risk, ALIVUS.NS is less volatile compared to ALIVUS.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check ALIVUS.BO's competition here
Glenmark Life Sciences Limited (NSE: GLS.NS)
ALIVUS.NS vs GLS.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GLS.NS's competition here
Glenmark Life Sciences Limited (BSE: GLS.BO)
ALIVUS.NS vs GLS.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GLS.BO's competition here
Shilpa Medicare Limited (NSE: SHILPAMED.NS)
ALIVUS.NS vs SHILPAMED.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SHILPAMED.NS has a market cap of 118.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SHILPAMED.NS trades at ₹606.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SHILPAMED.NS's P/E ratio is 46.81. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SHILPAMED.NS's competition here
Procter & Gamble Health Limited (NSE: PGHL.NS)
ALIVUS.NS vs PGHL.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, PGHL.NS has a market cap of 111.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while PGHL.NS trades at ₹6,714.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas PGHL.NS's P/E ratio is 34.10. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, ALIVUS.NS is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check PGHL.NS's competition here
Procter & Gamble Health Limited (BSE: PGHL.BO)
ALIVUS.NS vs PGHL.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, PGHL.BO has a market cap of 111.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while PGHL.BO trades at ₹6,723.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas PGHL.BO's P/E ratio is 37.26. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, ALIVUS.NS is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check PGHL.BO's competition here
Viyash Scientific Limited (NSE: VIYASH.NS)
ALIVUS.NS vs VIYASH.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, VIYASH.NS has a market cap of 109.5B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while VIYASH.NS trades at ₹250.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas VIYASH.NS's P/E ratio is 77.92. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, ALIVUS.NS is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check VIYASH.NS's competition here
Caplin Point Laboratories Limited (BSE: CAPPL.BO)
ALIVUS.NS vs CAPPL.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check CAPPL.BO's competition here
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS)
ALIVUS.NS vs AKUMS.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AKUMS.NS has a market cap of 105.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AKUMS.NS trades at ₹687.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AKUMS.NS's P/E ratio is 55.03. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, ALIVUS.NS is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check AKUMS.NS's competition here
Strides Pharma Science Limited (NSE: STAR.NS)
ALIVUS.NS vs STAR.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, STAR.NS has a market cap of 94B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while STAR.NS trades at ₹1,020.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas STAR.NS's P/E ratio is 16.92. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, ALIVUS.NS is more volatile compared to STAR.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check STAR.NS's competition here
Strides Pharma Science Limited (BSE: STAR.BO)
ALIVUS.NS vs STAR.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, STAR.BO has a market cap of 93.8B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while STAR.BO trades at ₹1,019.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas STAR.BO's P/E ratio is 16.90. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, ALIVUS.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check STAR.BO's competition here
Sudeep Pharma Ltd. (NSE: SUDEEPPHRM.NS)
ALIVUS.NS vs SUDEEPPHRM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SUDEEPPHRM.NS has a market cap of 93.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SUDEEPPHRM.NS trades at ₹825.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SUDEEPPHRM.NS's P/E ratio is 95.39. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, ALIVUS.NS is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SUDEEPPHRM.NS's competition here
Suven Life Sciences Limited (BSE: SUVEN.BO)
ALIVUS.NS vs SUVEN.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SUVEN.BO has a market cap of 71.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SUVEN.BO trades at ₹316.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SUVEN.BO's P/E ratio is -25.49. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SUVEN.BO's ROE of -0.87%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SUVEN.BO's competition here
Suven Life Sciences Limited (NSE: SUVEN.NS)
ALIVUS.NS vs SUVEN.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SUVEN.NS has a market cap of 71.3B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SUVEN.NS trades at ₹316.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SUVEN.NS's P/E ratio is -26.20. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SUVEN.NS's ROE of -0.87%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SUVEN.NS's competition here
Sun Pharma Advanced Research Company Limited (BSE: SPARC.BO)
ALIVUS.NS vs SPARC.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SPARC.BO has a market cap of 70.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SPARC.BO trades at ₹216.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SPARC.BO's P/E ratio is 4.52. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SPARC.BO's ROE of +14.36%. Regarding short-term risk, ALIVUS.NS is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check SPARC.BO's competition here
Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS)
ALIVUS.NS vs SPARC.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SPARC.NS has a market cap of 70.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SPARC.NS trades at ₹216.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SPARC.NS's P/E ratio is 4.52. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SPARC.NS's ROE of +14.36%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SPARC.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SPARC.NS's competition here
FDC Limited (NSE: FDC.NS)
ALIVUS.NS vs FDC.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, FDC.NS has a market cap of 67.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while FDC.NS trades at ₹412.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas FDC.NS's P/E ratio is 26.76. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, ALIVUS.NS is less volatile compared to FDC.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check FDC.NS's competition here
Aarti Pharmalabs Limited (NSE: AARTIPHARM.NS)
ALIVUS.NS vs AARTIPHARM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AARTIPHARM.NS has a market cap of 61.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AARTIPHARM.NS trades at ₹673.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AARTIPHARM.NS's P/E ratio is 23.29. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, ALIVUS.NS is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check AARTIPHARM.NS's competition here
Aarti Pharmalabs Limited (BSE: AARTIPHARM.BO)
ALIVUS.NS vs AARTIPHARM.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AARTIPHARM.BO has a market cap of 61.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AARTIPHARM.BO trades at ₹674.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AARTIPHARM.BO's P/E ratio is 32.54. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, ALIVUS.NS is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check AARTIPHARM.BO's competition here
Shilpa Medicare Limited (BSE: SHILPAMED.BO)
ALIVUS.NS vs SHILPAMED.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SHILPAMED.BO has a market cap of 59.2B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SHILPAMED.BO trades at ₹605.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SHILPAMED.BO's P/E ratio is 48.65. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is more volatile compared to SHILPAMED.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check SHILPAMED.BO's competition here
Innova Captab Limited (NSE: INNOVACAP.NS)
ALIVUS.NS vs INNOVACAP.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, INNOVACAP.NS has a market cap of 54.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while INNOVACAP.NS trades at ₹950.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas INNOVACAP.NS's P/E ratio is 44.69. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, ALIVUS.NS is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check INNOVACAP.NS's competition here
Sequent Scientific Limited (BSE: SEQUENT.BO)
ALIVUS.NS vs SEQUENT.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SEQUENT.BO's competition here
Sequent Scientific Limited (NSE: SEQUENT.NS)
ALIVUS.NS vs SEQUENT.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SEQUENT.NS's competition here
Orchid Pharma Limited (NSE: ORCHPHARMA.NS)
ALIVUS.NS vs ORCHPHARMA.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ORCHPHARMA.NS has a market cap of 50.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ORCHPHARMA.NS trades at ₹988.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ORCHPHARMA.NS's P/E ratio is 159.45. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, ALIVUS.NS is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check ORCHPHARMA.NS's competition here
Orchid Pharma Limited (BSE: ORCHPHARMA.BO)
ALIVUS.NS vs ORCHPHARMA.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, ORCHPHARMA.BO has a market cap of 50.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while ORCHPHARMA.BO trades at ₹987.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas ORCHPHARMA.BO's P/E ratio is 67.66. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, ALIVUS.NS is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check ORCHPHARMA.BO's competition here
Bliss GVS Pharma Limited (NSE: BLISSGVS.NS)
ALIVUS.NS vs BLISSGVS.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, BLISSGVS.NS has a market cap of 49.3B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while BLISSGVS.NS trades at ₹464.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas BLISSGVS.NS's P/E ratio is 38.56. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to BLISSGVS.NS's ROE of +0.11%. Regarding short-term risk, ALIVUS.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check BLISSGVS.NS's competition here
Bliss GVS Pharma Limited (BSE: BLISSGVS.BO)
ALIVUS.NS vs BLISSGVS.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, BLISSGVS.BO has a market cap of 49.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while BLISSGVS.BO trades at ₹463.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas BLISSGVS.BO's P/E ratio is 38.47. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to BLISSGVS.BO's ROE of +0.11%. Regarding short-term risk, ALIVUS.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check BLISSGVS.BO's competition here
RPG Life Sciences Limited (BSE: RPGLIFE.BO)
ALIVUS.NS vs RPGLIFE.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, RPGLIFE.BO has a market cap of 48.7B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while RPGLIFE.BO trades at ₹2,913.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas RPGLIFE.BO's P/E ratio is 41.83. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, ALIVUS.NS is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check RPGLIFE.BO's competition here
RPG Life Sciences Limited (NSE: RPGLIFE.NS)
ALIVUS.NS vs RPGLIFE.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, RPGLIFE.NS has a market cap of 48.6B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while RPGLIFE.NS trades at ₹2,937.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas RPGLIFE.NS's P/E ratio is 42.17. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, ALIVUS.NS is less volatile compared to RPGLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check RPGLIFE.NS's competition here
IOL Chemicals and Pharmaceuticals Limited (BSE: IOLCP.BO)
ALIVUS.NS vs IOLCP.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, IOLCP.BO has a market cap of 43.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while IOLCP.BO trades at ₹149.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas IOLCP.BO's P/E ratio is 29.29. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, ALIVUS.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check IOLCP.BO's competition here
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP.NS)
ALIVUS.NS vs IOLCP.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, IOLCP.NS has a market cap of 43.8B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while IOLCP.NS trades at ₹149.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas IOLCP.NS's P/E ratio is 29.37. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, ALIVUS.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check IOLCP.NS's competition here
Novartis India Limited (BSE: NOVARTIND.BO)
ALIVUS.NS vs NOVARTIND.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, NOVARTIND.BO has a market cap of 40.7B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while NOVARTIND.BO trades at ₹1,647.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas NOVARTIND.BO's P/E ratio is 42.86. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, ALIVUS.NS is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check NOVARTIND.BO's competition here
Novartis India Limited (NSE: NOVARTIND.NS)
ALIVUS.NS vs NOVARTIND.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, NOVARTIND.NS has a market cap of 40.1B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while NOVARTIND.NS trades at ₹1,641.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas NOVARTIND.NS's P/E ratio is 42.71. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, ALIVUS.NS is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check NOVARTIND.NS's competition here
Gujarat Themis Biosyn Ltd. (NSE: GUJTHEM.NS)
ALIVUS.NS vs GUJTHEM.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GUJTHEM.NS has a market cap of 39.3B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GUJTHEM.NS trades at ₹360.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GUJTHEM.NS's P/E ratio is 83.84. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GUJTHEM.NS's competition here
Gufic Biosciences Limited (NSE: GUFICBIO.NS)
ALIVUS.NS vs GUFICBIO.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GUFICBIO.NS has a market cap of 38B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GUFICBIO.NS trades at ₹378.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GUFICBIO.NS's P/E ratio is 59.20. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GUFICBIO.NS's competition here
Gufic Biosciences Limited (BSE: GUFICBIO.BO)
ALIVUS.NS vs GUFICBIO.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, GUFICBIO.BO has a market cap of 38B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while GUFICBIO.BO trades at ₹378.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas GUFICBIO.BO's P/E ratio is 59.10. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check GUFICBIO.BO's competition here
Unichem Laboratories Limited (NSE: UNICHEMLAB.NS)
ALIVUS.NS vs UNICHEMLAB.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, UNICHEMLAB.NS has a market cap of 37.8B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while UNICHEMLAB.NS trades at ₹537.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas UNICHEMLAB.NS's P/E ratio is 14.96. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check UNICHEMLAB.NS's competition here
Unichem Laboratories Limited (BSE: UNICHEMLAB.BO)
ALIVUS.NS vs UNICHEMLAB.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, UNICHEMLAB.BO has a market cap of 37.8B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while UNICHEMLAB.BO trades at ₹539.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas UNICHEMLAB.BO's P/E ratio is 15.02. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, ALIVUS.NS is more volatile compared to UNICHEMLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check UNICHEMLAB.BO's competition here
Aarti Drugs Limited (NSE: AARTIDRUGS.NS)
ALIVUS.NS vs AARTIDRUGS.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AARTIDRUGS.NS has a market cap of 36.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AARTIDRUGS.NS trades at ₹404.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AARTIDRUGS.NS's P/E ratio is 19.04. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, ALIVUS.NS is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check AARTIDRUGS.NS's competition here
Aarti Drugs Limited (BSE: AARTIDRUGS.BO)
ALIVUS.NS vs AARTIDRUGS.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, AARTIDRUGS.BO has a market cap of 36.9B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while AARTIDRUGS.BO trades at ₹404.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas AARTIDRUGS.BO's P/E ratio is 19.04. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, ALIVUS.NS is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for ALIVUS.NS.Check AARTIDRUGS.BO's competition here
Morepen Laboratories Limited (BSE: MOREPENLAB.BO)
ALIVUS.NS vs MOREPENLAB.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, MOREPENLAB.BO has a market cap of 29.5B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while MOREPENLAB.BO trades at ₹53.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas MOREPENLAB.BO's P/E ratio is 31.09. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, ALIVUS.NS is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check MOREPENLAB.BO's competition here
Morepen Laboratories Limited (NSE: MOREPENLAB.NS)
ALIVUS.NS vs MOREPENLAB.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, MOREPENLAB.NS has a market cap of 29.5B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while MOREPENLAB.NS trades at ₹53.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas MOREPENLAB.NS's P/E ratio is 28.62. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, ALIVUS.NS is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check MOREPENLAB.NS's competition here
Solara Active Pharma Sciences Limited (NSE: SOLARA.NS)
ALIVUS.NS vs SOLARA.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SOLARA.NS has a market cap of 23.7B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SOLARA.NS trades at ₹491.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SOLARA.NS's P/E ratio is 279.52. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SOLARA.NS's ROE of -0.00%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SOLARA.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SOLARA.NS's competition here
Solara Active Pharma Sciences Limited (BSE: SOLARA.BO)
ALIVUS.NS vs SOLARA.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, SOLARA.BO has a market cap of 23.7B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while SOLARA.BO trades at ₹490.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas SOLARA.BO's P/E ratio is 357.92. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to SOLARA.BO's ROE of -0.00%. Regarding short-term risk, ALIVUS.NS is less volatile compared to SOLARA.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check SOLARA.BO's competition here
Indoco Remedies Limited (NSE: INDOCO.NS)
ALIVUS.NS vs INDOCO.NS Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, INDOCO.NS has a market cap of 22.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while INDOCO.NS trades at ₹243.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas INDOCO.NS's P/E ratio is -17.30. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to INDOCO.NS's ROE of -0.10%. Regarding short-term risk, ALIVUS.NS is less volatile compared to INDOCO.NS. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check INDOCO.NS's competition here
Indoco Remedies Limited (BSE: INDOCO.BO)
ALIVUS.NS vs INDOCO.BO Comparison July 2026
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALIVUS.NS stands at 135.2B. In comparison, INDOCO.BO has a market cap of 22.4B. Regarding current trading prices, ALIVUS.NS is priced at ₹1,101.20 on the NSE, while INDOCO.BO trades at ₹242.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALIVUS.NS currently has a P/E ratio of 41.01, whereas INDOCO.BO's P/E ratio is -23.26. In terms of profitability, ALIVUS.NS's ROE is +0.18%, compared to INDOCO.BO's ROE of -0.10%. Regarding short-term risk, ALIVUS.NS is less volatile compared to INDOCO.BO. This indicates lower risk in terms of short-term price fluctuations for ALIVUS.NS.Check INDOCO.BO's competition here